User:Mr. Ibrahem/Ubrogepant

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ubrogepant
Clinical data
Trade namesUbrelvy
Other namesMK-1602
AHFS/Drugs.comMonograph
MedlinePlusa620016
License data
Routes of
administration		By mouth
Drug classCalcitonin gene-related peptide receptor antagonist[1]
Legal status
Legal status
Identifiers
  • (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
Chemical and physical data
FormulaC29H26F3N5O3
Molar mass549.554 g·mol−1
3D model (JSmol)
  • CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6
  • InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
  • Key:DDOOFTLHJSMHLN-ZQHRPCGSSA-N

Ubrogepant, sold under the brand name Ubrelvy, is a medication used to treat migraine attacks.[1] This includes whether or not an aura was present.[1] It is not used for migraine prevention.[3] It is taken by mouth.[1]

Common side effects include nausea, tiredness and dry mouth.[1] Safety during pregnancy or breastfeeding is unclear.[4] Use is not recommended together with strong CYP3A4 inhibitors or inducers.[1] It is a small-molecule calcitonin gene-related peptide receptor antagonist.[1]

Ubrogepant was approved for medical use in the United States in 2019.[1][5] In the United States it costs about 87 USD per 100 mg tablet as of 2021.[6] It has not been approved in Europe as of 2021.[7]

References[edit]

  1. ^ a b c d e f g h i j k l "Ubrogepant Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 August 2021.
  2. ^ "Ubrelvy- ubrogepant tablet". DailyMed. Archived from the original on 4 June 2021. Retrieved 4 June 2021.
  3. ^ "FDA approves new treatment for adults with migraine". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Ubrogepant (Ubrelvy) Use During Pregnancy". Drugs.com. Archived from the original on 5 March 2021. Retrieved 12 August 2021.
  5. ^ Scott, LJ (February 2020). "Ubrogepant: First Approval". Drugs. 80 (3): 323–328. doi:10.1007/s40265-020-01264-5. PMID 32020557.
  6. ^ "Ubrogepant Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 12 August 2021.
  7. ^ "Ubrogepant". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 13 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ubrogepant&oldid=1206943796"